57
Participants
Start Date
August 24, 2020
Primary Completion Date
November 3, 2023
Study Completion Date
June 30, 2024
RC48-ADC
The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.5 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first)
Anhui Provincial Cancer Hospital, Hefei
Beijing 302 Hospital/5th Medical Center of Chinese PLA General of Hospital, Beijing
Peking University Cancer Hospital & Institute, Beijing
The First Hospital Affiliated to AMU (Southwest Hospital), Chongqing
Sun Yat-Sen university Cancer Center, Guangzhou
Hunan Cancer Hospital, Changsha
First Hospital of Jilin University, Changchun
Shandong Cancer Hospital Affiliated to Shandong University, Jinan
Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai
Xinhua Hospital, Shanghai
Zhongshan Hospital, Fudan University, Shanghai
West China Hospital, Sichuan University, Chengdu
Tianjin Cancer Hospital, Tianjin
The First Affiliated Hospital, Zhejiang University, Hangzhou
Fudan University Shanghai Cancer Center, Shanghai
Tongji University Shanghai East Hospital, Shanghai
RemeGen Co., Ltd.
INDUSTRY